Importantly, the specificity of our antibodies to the three major BCL-2 family heterodimer protein complexes (i.e., BCL-2, MCL-1, and BCL-XL with BIM) that dictate cancer cell priming was validated here using both purified proteins and cells, including knockdown/knockout lines. The gene discussed is BCL2L11; the disease is cancer.